The Omnipod 5 Automated Insulin Delivery System is now commercially available in Australia, launching soon in Belgium, Canada, and Switzerland.
ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its revolutionary Omnipod 5 Automated Insulin Delivery (AID) System is now available in Australia and will soon be offered in three additional countries, helping transform the lives of thousands more people with diabetes around the world.
- Omnipod 5 is now commercially available in Australia with Dexcom G6 and G7 compatibility, with plans underway to soon add Abbott’s FreeStyle Libre® 2 Plus.
- Omnipod 5 will be accessible in Belgium in the coming weeks, with Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 and G7 sensor integrations.
- Omnipod 5 will next launch in Canada later this spring with Dexcom G6 and G7 compatibility.
- Omnipod 5 will also be offered in Switzerland, also later this spring, with Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 and G7 sensor integrations.
Insulet also recently expanded sensor integrations to include Dexcom G7 for Omnipod 5 users in the U.K. and the Netherlands. Additionally, Insulet is planning to bring Omnipod 5 to five more markets including Israel, Saudi Arabia, the United Arab Emirates, Qatar, and Kuwait. Timing will be shared in the coming months.
“Bringing our life-changing flagship Omnipod 5 to people living with diabetes in these four new countries is both incredibly exciting and meaningful, further cementing our leadership position worldwide,” said Pat Crannell, Senior Vice President and International General Manager. “We’re transforming diabetes management, delivering real-world benefits for our customers to help make diabetes a smaller part of their busy lives.”
The Omnipod 5 System simplifies diabetes management and has shown to improve clinical outcomes by eliminating the need for multiple daily injections (MDI) and automatically adjusting insulin delivery every five minutes using its advanced SmartAdjust™ technology. The waterproof 1, discreet, and wearable Omnipod 5 is the first tubeless AID system that communicates with a continuous glucose monitor, proactively correcting for highs and helping to protect against lows, day and night 2,3.
Kimmie Patel, who lives in Australia and whose five-year-old daughter, Priya, currently uses Omnipod® DASH, is looking forward to the latest innovation. “We’re really excited for Priya to start on Omnipod 5. She’s a bright, energetic little girl and managing her diabetes has always been a part of her routine. School is such an important part of her life now, and knowing that she can just be a kid without constantly worrying about her insulin delivery is a huge relief. Omnipod 5 should give her even more confidence to enjoy every moment.”
“Canadians living with type 1 diabetes have been anxiously awaiting the arrival of Omnipod 5, the only tubeless commercial AID System. In keeping with our new Diabetes Canada Guidelines that all people with type 1 diabetes should use an AID System, the arrival of Omnipod 5 will be life changing for many people living with diabetes and their families,” said Dr. Ilana Halperin, an endocrinologist at Sunnybrook Health Sciences Centre in Toronto, Canada.
Today’s announcement was made before the 18th International Conference on Advanced Technologies & Treatments for Diabetes, where the Company will present new clinical data assessing the direct transition from multiple daily injections to Omnipod 5 in adults and children with type 1 diabetes.
This news follows Insulet’s announcement in January about Omnipod 5 launches Italy and the Nordics that were enthusiastically received by customers and healthcare providers, which followed equally successful launches in the U.S., U.K., Germany, France, and the Netherlands.
|
1 The Pod has an IP28 rating for up to 7.6 meters (25 feet) for 60 minutes. The Omnipod 5 Controller is not waterproof. |
|
2 Sherr JL, et al. Diabetes Care (2022). Study in 80 people with type 1 diabetes (T1D) aged 2 – 5.9 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode. |
|
3 Brown et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 – 70 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode. |
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: insulet.com and omnipod.com.
Forward-Looking Statement:
This press release may contain forward-looking statements concerning Insulet’s expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 21, 2025 in the section entitled “Risk Factors,” and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary materially from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. Dexcom is a registered trademark of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners.
Contacts
Investor Relations:
June Lazaroff
Senior Director, Investor Relations
(978) 600-7717
[email protected]
Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
[email protected]
